Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

NCT ID: NCT02233751

Last Updated: 2019-04-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-30
• Study Completion Date: 2014-10-31

Brief Summary

Evaluation of pharmacokinetics of subcutaneous testosterone enanthate

Detailed Description

Evaluation of pharmacokinetics and safety profile of testosterone enanthate injected subcutaneously via auto-injector in healthy male volunteers

Conditions

Hypogonadism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Testosterone enanthate auto-injector - 50 mg

Testosterone enanthate auto-injector - 50 mg (SC injection)

Group Type: EXPERIMENTAL

Testosterone enanthate auto-injector

Intervention Type: COMBINATION_PRODUCT

Randomization then administration of combination product study medication according to group assignment

Testosterone enanthate auto-injector - 200 mg

Testosterone enanthate auto-injector- 200 mg (SC injection)

Group Type: EXPERIMENTAL

Testosterone enanthate auto-injector

Intervention Type: COMBINATION_PRODUCT

Randomization then administration of combination product study medication according to group assignment

Interventions

Testosterone enanthate auto-injector

Randomization then administration of combination product study medication according to group assignment

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

• Healthy adult male subjects, 18-55 years of age, inclusive, at the time of signing the informed consent;
• Body weight ≥50 kg and body mass index within the range 19-30 kg/m2, inclusive, at screening;
• Medically healthy subjects with clinically insignificant screening and check-in results (medical history, 12-lead electrocardiogram [ECG], physical examination, and laboratory tests); and
• Subjects who are able to understand and are willing and able to give their signed informed consent before any trial-related procedures are performed.

Exclusion Criteria

• Currently diagnosed or a history of asthma, urticarial, angioedema, anaphylaxis, atopic dermatitis, clinically significant abnormality of skin of the abdomen, cancer, diabetes, or any other clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, hematological, dermatological, venereal, neurological, psychiatric, or other major disorders;
• History of benign prostate hypertrophy (BPH), prostate cancer, or abnormal prostate specific antigen (PSA) values;
• PSA level > 3 ng/ml at screening;
• Presence or history of gastrointestinal, hepatic or renal disease, or any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines;
• Systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 40 to 90 mmHg, and/or pulse rate outside the range of 40 to 100 beats per minute after one repeat at screening or check-in;
• Abnormal ECG at screening as judged by the Investigator;
• History of clinically significant drug and/or food allergies as determined by the Investigator;
• Allergy to sesame, sesame oil, or a history of hypersensitivity or idiosyncratic reaction to compounds related to the study drug
• Subjects undergoing current treatment with other androgens (i.e. dehydroepiandrosterone [DHEA]), anabolic steroids, other sex hormones, or drugs that interfere with the metabolism of testosterone (i.e. opioids, anastrozole, clomiphene, dutasteride, finasteride, flutamide, ketoconazole, spironolactone, and testolactone);
• Subjects treated within the past 12 months with estrogens, gonadotropin releasing hormone (GnRH) agonists, or growth hormone;
• Prescription, over the counter medications, vitamins, herbal and dietary supplements taken within 7 days or 5 half-lives (whichever is longer) prior to the dose of study medication and duration of the study;
• Positive screen for human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C at screening;
• Positive urine screen for drugs of abuse (amphetamine, barbiturates, benzodiazepines, cocaine, marijuana, methadone, methamphetamines, oxycodone, and opiates) or positive breath alcohol test at screening and check-in

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Antares Pharma Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan Jaffe, MD

Role: STUDY_DIRECTOR

Antares Pharma Inc.

Locations

Medpace Clinical Pharmacology Unit

Cincinnati, Ohio, United States

Countries

United States

Other Identifiers

QST-14-004

Identifier Type: -

Identifier Source: org_study_id